REGN — Regeneron Pharmaceuticals, Inc.

Summary of Regeneron Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $3.9 billion, up 3% year-over-year.
• Net Income: $1.2 billion, with diluted earnings per share of $11.44.
• DUPIXENT Sales: $4.9 billion in Q4, 32% year-over-year growth; $17.8 billion for the full year.
• LIBTAYO Sales: $425 million in Q4, 13% year-over-year growth.
• EYLEA HD Sales: $506 million in Q4, 66% growth; $1.6 billion for the full year.
• Free Cash Flow: $4.1 billion for 2025.
• Shareholder Returns: $3.8 billion returned, primarily through share repurchases.

2. Strategic Updates and Business Highlights

• DUPIXENT: Now approved in 8 indications, with significant growth potential as many indications remain under-penetrated.
• LIBTAYO: Gaining traction in advanced non-small cell lung cancer and recently approved for adjuvant cutaneous squamous cell carcinoma (CSCC).
• EYLEA HD: Recent FDA approvals for monthly dosing and for treating retinal vein occlusion (RVO) enhance its market position.
• Pipeline Expansion: Plans for at least 4 FDA approvals in 2026, including new molecular entities and the EYLEA HD prefilled syringe.
• R&D Investments: Continued focus on expanding the pipeline with 18 Phase III studies planned, targeting approximately 35,000 patients.

3. Forward Guidance and Outlook

• 2026 R&D Spending: Expected to be between $5.9 billion and $6.1 billion.
• SG&A Expenses: Anticipated to be between $2.5 billion and $2.65 billion.
• Gross Margin: Expected to be between 83% and 84%.
• Effective Tax Rate: Projected to be between 13% and 15%.
• EYLEA HD Demand: Anticipated high single-digit growth in Q1 2026, while EYLEA 2 mg expected to decline due to competitive pressures.

4. Challenges and Points of Concern

• EYLEA 2 mg Sales Decline: Experienced a 15% sequential decline in Q4, facing increasing competition from biosimilars expected to launch in H2 2026.
• Patient Affordability Issues: Ongoing concerns about patient co-pay affordability impacting growth in the anti-VEGF category.
• Regulatory Risks: Potential delays or challenges in FDA approvals for new products and enhancements.
• Competitive Landscape: Increasing competition in multiple therapeutic areas, particularly in oncology and ophthalmology.

5. Notable Q&A Insights

• LIBTAYO Data Timeline: Expected readouts for advanced melanoma and adjuvant studies in the first half of 2026, though specific timing remains uncertain.
• DUPIXENT Intellectual Property: Discussions about extending the product's market exclusivity into the 2040s, with ongoing development of next-generation formulations.
• Geographic Atrophy Program: Differentiated approach combining systemic and local treatments, with primary endpoints focused on GA lesion growth and secondary endpoints on visual acuity.
• GLP-1/GIP Combination Therapy: Emphasis on the unique value proposition of combining weight loss and cholesterol-lowering benefits in a single injection, with confidence stemming from prior studies in China.

Overall, Regeneron demonstrated solid financial performance in Q4 2025, with strong growth in key products and an ambitious pipeline for 2026. However, challenges such as competitive pressures and patient affordability issues remain critical areas of focus.